Aurinia Pharmaceuticals Inc.
auriniapharma.comWhat Do They Do?
Sells LUPKYNIS, an oral treatment for adults with active lupus nephritis, through specialty pharmacies, a specialty distributor and a pharmaceutical partner; develops aritinercept for potential autoimmune-disease treatment.
10-K for FY2025, filed Feb 26, 2026Aurinia is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical…View ↗
Aurinia sells LUPKYNIS to two specialty pharmacies and a specialty distributor in the United States (“U.S.”), and Aurinia sells LUPKYNIS…View ↗
In January 2021, the Company introduced LUPKYNIS, the first FDA-approved oral therapy for the treatment of adult patients with active LN.…View ↗
How Do They Make Money?
Customers buy LUPKYNIS inventory, with sales tied to delivery and standard credit terms of 30 to 45 days. Otsuka also pays upfront license fees, milestones when achieved, royalties as territory sales occur, and for manufacturing and other services.
10-K for FY2025, filed Feb 26, 2026The Company sells LUPKYNIS to two specialty pharmacies and a specialty distributor in the U.S., and the Company sells LUPKYNIS inventory to…View ↗
Revenue from product sales is recognized when the customer obtains control of the Company's product, which typically occurs on delivery.…View ↗
The Company’s major customers, which include two specialty pharmacies and its collaboration partner, Otsuka Pharmaceutical Co., Ltd…View ↗
The Company enters into out-license agreements with counterparties to develop and commercialize LUPKYNIS in certain ex-U.S. territories in…View ↗
At the inception of each arrangement that includes commercial sales milestone payments, the Company evaluates whether achieving each…View ↗
For arrangements that include sales-based royalties, revenue is recognized when the underlying product sales have occurred. Revenue is…View ↗
-
10-K for FY2025, filed Feb 26, 2026
FY2025 revenue by product or service ↗
$283.1M
-
10-K for FY2025, filed Feb 26, 2026
$283.1M ↗
| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Net product sales
Sold outright
10-K for FY2025, filed Feb 26, 2026 |
96%
FY2022: 77%
|
Net product sales, FY2025
$271.3M Sources
|
Sold outright |
|
License, collaboration and royalty revenue
Licensed
|
4.1%
FY2022: 23%
|
License, collaboration and royalty revenue, FY2025
$11.7M Sources
|
Licensed |
Who Are Their Customers?
U.S. sales go to specialty pharmacies and a specialty distributor; Otsuka buys inventory for the European and Japanese markets and markets LUPKYNIS there.
10-K for FY2025, filed Feb 26, 2026
Do Revenues Turn Into Profits?
Yes. Its net income in FY2025 was larger than its revenue.
10-K for FY2025, filed Feb 26, 2026
How Are They Changing?
10-Q for Q2 FY2026, filed Aug 6, 2026
Open tableView ↗
-
Aug 6, 2026
Aurinia reiterated revenue and product-sales guidance
It maintained total revenue guidance of $315 million to $325 million and net product sales guidance of $305 million to $315 million.
Sources
8-K, filed Aug 6, 2026
Aurinia reiterates its guidance for 2026 total revenue of $315 million to $325 million, up 11% to 15% compared to 2025, and 2026 net…View ↗
-
May 11, 2026
Aurinia completed its acquisition of Kezar
Kezar became a wholly owned subsidiary following the tender offer and merger.
Sources
8-K, filed May 11, 2026
Pursuant to the Merger Agreement, and upon the terms and subject to the conditions thereof, on May 8, 2026, Parent completed a tender offer…View ↗
-
Mar 23, 2026
Kevin Tang replaced Peter Greenleaf as CEO; Michael Hearne became CFO
Sources
8-K, filed Mar 23, 2026
Effective March 23, 2026, the Board of Directors of Aurinia Pharmaceuticals Inc. (“Aurinia”) appointed Kevin Tang as Aurinia’s Chief…View ↗
Growing. Revenue grew 6.2x in 4 years, from $45.6M in FY2021 to $283.1M in FY2025, about 58% a year.
A licensed pipeline program
The older report described a preclinical program licensed from Riptide Biosciences; the latest says the program was discontinued and highlights continued LUPKYNIS growth and aritinercept development.
10-K for FY2022, filed Feb 28, 2023 10-K for FY2025, filed Feb 26, 2026On August 17, 2021, we announced the addition of two newly acquired novel assets AUR200 and AUR300. AUR300 is exclusively licensed from…View ↗
Restructuring expense consists primarily of one-time termination benefits to affected employees, including severance and health care…View ↗
Who Do They Compete With?
Competes with GSK and Genentech
10-K for FY2025, filed Feb 26, 2026The pharmaceutical industry is competitive. While LUPKYNIS is the only FDA-approved oral therapy for the treatment of adult patients with…View ↗
Loading...
